TSS
MCID: TXC005
MIFTS: 60

Toxic Shock Syndrome (TSS) malady

Categories: Infectious diseases

Aliases & Classifications for Toxic Shock Syndrome

Aliases & Descriptions for Toxic Shock Syndrome:

Name: Toxic Shock Syndrome 12 52 14 69
Staphylococcal Toxic Shock Syndrome 69
Shock, Septic 42
Toxic Shock 12
Tss 12

Classifications:



External Ids:

Disease Ontology 12 DOID:14115
ICD10 33 A48.3 R57.2
ICD9CM 35 040.82
MeSH 42 D012772
NCIt 47 C35498
SNOMED-CT 64 18504008
UMLS 69 C0600327

Summaries for Toxic Shock Syndrome

Disease Ontology : 12 A commensal bacterial infectious disease that results_in infection, has material basis in Streptococcus pyogenes or has material basis in Staphylococcus aureus , which produce toxins that are absorbed systemically and produce the systemic manifestations. The infection has symptom fever, has symptom rash, has symptom hypotension, has symptom multiorgan failure, has symptom desquamation, has symptom vomiting, has symptom diarrhea, has symptom headache, and has symptom nonfocal neurologic abnormalities.

MalaCards based summary : Toxic Shock Syndrome, also known as staphylococcal toxic shock syndrome, is related to burns and breast reconstruction, and has symptoms including fever, rash and hypotension. An important gene associated with Toxic Shock Syndrome is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ephedrine and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and monocytes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Wikipedia : 71 Toxic shock syndrome (TSS) is a potentially fatal illness caused by a bacterial toxin. Different... more...

Related Diseases for Toxic Shock Syndrome

Diseases related to Toxic Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 376)
id Related Disease Score Top Affiliating Genes
1 burns 30.4 CXCL8 IFNG IL10 IL6 TNF
2 breast reconstruction 30.0 IL10 IL1B IL6
3 measles 29.8 IL1B IL6 TNF
4 tracheitis 29.8 CXCL8 IFNG IL2 IL4 TNF
5 neuropathy 29.6 CXCL8 IL1B IL6 TNF
6 limb ischemia 29.6 CXCL8 IL6 TNF
7 choroiditis 29.3 CXCL8 IL10 IL1B IL6 TNF
8 hepatitis 29.3 IFNG IL10 IL2 IL6 TNF
9 rheumatoid arthritis 28.7 CIITA CXCL8 HMGB1 IFNG IL10 IL1B
10 staphylococcal toxic shock syndrome 12.4
11 streptococcal toxic-shock syndrome 12.3
12 staphylococcal scarlet fever 11.3
13 clostridium sordellii infection 11.3
14 intussusception 10.4 IL1B TNF
15 kaposiform hemangioendothelioma 10.3 IL2 LTA
16 steatitis 10.3 IL2 TNF
17 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.3 IL6 TNF
18 anal paget's disease 10.3 IL1B IL6 TNF
19 drug dependence 10.3 IL6 LTA TNF
20 human immunodeficiency virus infectious disease 10.3 IL1B IL6 TNF
21 steroid dehydrogenase deficiency dental anomalies 10.3 IL1B IL6 TNF
22 benign neonatal seizures 10.3 IL1B IL6 TNF
23 mineral metabolism disease 10.3 IL1B IL6 TNF
24 migraine with aura 10.3 IL1B IL6 TNF
25 laryngotracheoesophageal cleft type 2 10.3 IL1B IL2 IL6
26 keratoconus 10.3 IL1B IL6 TNF
27 motility-related diarrhea 10.3 IL1B IL6 TNF
28 splenic artery aneurysm 10.3 IL1B IL6 TNF
29 oculomotor nerve paralysis 10.3 CXCL8 IL1B IL6
30 common peroneal nerve lesion 10.3 CXCL8 IL1B IL6
31 pancreas lymphoma 10.3 IL1B IL6 TNF
32 cicatricial lagophthalmos 10.3 CXCL8 IL6 TNF
33 bullous retinoschisis 10.3 CXCL8 IL1B IL6
34 carbuncle 10.3 CXCL8 IL1B IL6
35 larynx leiomyoma 10.3 CXCL8 IL1B IL6
36 choanal atresia, bilateral 10.3 CIITA IL6 TNF
37 ovarian cystic teratoma 10.2 CXCL8 IL1B TNF
38 parametritis 10.2 IFNG IL2 TNF
39 stickler syndrome, type v 10.2 IL1B IL2 IL6
40 nasal cavity cancer 10.2 CXCL8 IL1B TNF
41 venezuelan hemorrhagic fever 10.2 IFNG IL2 TNF
42 pyridoxal 5'-phosphate-dependent epilepsy 10.2 IL10 TNF
43 uterine adnexa cancer 10.2 IL1B IL6 TNF
44 angiomatosis, diffuse corticomeningeal, of divry and van bogaert 10.2 HMGB1 IL6 TNF
45 acute allergic sanguinous otitis media 10.2 IL2 IL6 MYOM2
46 wilkes stevenson syndrome 10.2 CXCL8 IL1B IL2
47 wound botulism 10.2 IL1B MYOM2 TNF
48 glucose intolerance 10.2 CXCL8 IFNG TNF
49 myoglobinuria recurrent 10.2 IFNG IL4
50 fasciitis 10.2

Graphical network of the top 20 diseases related to Toxic Shock Syndrome:



Diseases related to Toxic Shock Syndrome

Symptoms & Phenotypes for Toxic Shock Syndrome

Symptoms:

12
  • fever
  • rash
  • hypotension
  • multiorgan failure
  • desquamation
  • vomiting
  • diarrhea
  • headache
  • nonfocal neurologic abnormalities

UMLS symptoms related to Toxic Shock Syndrome:


shock without mention of trauma

GenomeRNAi Phenotypes related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.72 IL10 IL1B IL2 LTA TNF CXCL8
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.72 IL1B IL2 LTA TNF CXCL8 IL10

MGI Mouse Phenotypes related to Toxic Shock Syndrome:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.23 IFNG IL10 IL1B IL2 IL4 IL6
2 homeostasis/metabolism MP:0005376 10.21 CD40 CIITA EDNRA IFNG IL10 IL1B
3 endocrine/exocrine gland MP:0005379 10.18 IL6 LTA TNF CD40 CIITA EDNRA
4 immune system MP:0005387 10.18 CD40 CIITA EDNRA IFNG IL10 IL1B
5 cardiovascular system MP:0005385 10.16 TNF EDNRA IFNG IL10 IL1B IL2
6 digestive/alimentary MP:0005381 10.04 EDNRA IFNG IL10 IL2 IL4 IL6
7 liver/biliary system MP:0005370 9.97 IL4 IL6 LTA SERPINC1 TNF IFNG
8 nervous system MP:0003631 9.96 CD40 EDNRA IFNG IL10 IL1B IL4
9 neoplasm MP:0002006 9.8 IFNG IL10 IL1B IL2 IL6 TNF
10 respiratory system MP:0005388 9.76 EDNRA IFNG IL10 IL2 IL4 IL6
11 skeleton MP:0005390 9.65 CD40 CIITA EDNRA IFNG IL10 IL1B
12 vision/eye MP:0005391 9.28 EDNRA IFNG IL10 IL2 IL4 IL6

Drugs & Therapeutics for Toxic Shock Syndrome

Drugs for Toxic Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 443)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ephedrine Approved Phase 4,Phase 2 299-42-3 9294
2
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
3
Oxymetazoline Approved Phase 4,Phase 2 1491-59-4 4636
4
Phenylephrine Approved Phase 4,Phase 2 59-42-7 6041
5
Pseudoephedrine Approved Phase 4,Phase 2 90-82-4 7028
6
Simvastatin Approved Phase 4,Phase 2,Phase 3 79902-63-9 54454
7
Ceftriaxone Approved Phase 4,Phase 3 73384-59-5 5479530 5361919
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
10
Dobutamine Approved Phase 4,Phase 2,Phase 3 34368-04-2 36811
11
Meropenem Approved, Investigational Phase 4,Phase 2,Phase 3 119478-56-7 64778 441130
12
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-23-7 5754 657311
13
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
14
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 6740-88-1 3821
15
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
16
Piperacillin Approved Phase 4,Phase 2,Phase 3 66258-76-2 43672
17
Tazobactam Approved Phase 4,Phase 2,Phase 3 89786-04-9 123630
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
19
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
20
Amikacin Approved, Vet_approved Phase 4 37517-28-5 37768
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
22
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
23
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 2078-54-8 4943
24
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
25
Adenosine Approved, Investigational Phase 4,Phase 1 58-61-7 60961
26
Dipyridamole Approved Phase 4 58-32-2 3108
27
Copper Approved Phase 4 15158-11-9, 7440-50-8 27099
28
Nitroglycerin Approved, Investigational Phase 4,Phase 3 55-63-0 4510
29
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
30
Clarithromycin Approved Phase 4,Phase 3 81103-11-9 84029
31
Etomidate Approved Phase 4 33125-97-2 36339 667484
32
Amiodarone Approved, Investigational Phase 4,Phase 2,Phase 3 1951-25-3 2157
33
Mexiletine Approved Phase 4 31828-71-4 4178
34
Milrinone Approved Phase 4 78415-72-2 4197
35
Midodrine Approved Phase 4,Phase 3 133163-28-7, 42794-76-3 4195
36
Propafenone Approved Phase 4 54063-53-5 4932
37
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
38
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
39
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
40
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
41
Rifampin Approved Phase 4 13292-46-1 5458213 5381226
42
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
43 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
44
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
45
Vitamin C Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-81-7 5785 54670067
46
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
47
Butyric Acid Experimental Phase 4,Phase 2,Phase 3,Phase 1 107-92-6 264
48
Methylene blue Investigational Phase 4,Phase 3,Phase 1 61-73-4
49 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
50 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 656)
id Name Status NCT ID Phase
1 A Pilot Trial of Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients Unknown status NCT02203630 Phase 4
2 Simvastatin in Patients With Septic Shock Unknown status NCT00450840 Phase 4
3 Early Continuous Renal Replacement Therapies (CRRT) in Patients With Severe Sepsis or Septic Shock With Acute Kidney Injury Unknown status NCT00837057 Phase 4
4 Pharmacokinetic of Ceftriaxone in Septic ICU Patients Unknown status NCT00449800 Phase 4
5 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4
6 Targeting the Microcirculation in Resuscitation of Patients With Septic Shock Completed NCT02085291 Phase 4
7 Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock Completed NCT01310790 Phase 4
8 The Effect of Dexmedetomidine on Microcirculation in Septic Shock Completed NCT02270281 Phase 4
9 Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units Completed NCT02213796 Phase 4
10 Microcirculation After MAP Increase in Septic Shock Patients With Previous Hypertension Completed NCT02519699 Phase 4
11 Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C Completed NCT02885168 Phase 4
12 Early Albumin Resuscitation During Septic Shock Completed NCT00327704 Phase 4
13 Hydrocortisone 50 mg Every 6 Hours Compared to Hydrocortisone 300 mg Per Day in Treatment of Septic Shock. Completed NCT02768740 Phase 4
14 High MAP in Septic Shock With Hypertension Completed NCT01443494 Phase 4
15 Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock Completed NCT00279214 Phase 4
16 Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Completed NCT02079402 Phase 4
17 Dex on Microcirculation in SS—A Double-blinded Study Completed NCT02612181 Phase 4
18 Norepinephrine Weaning in Septic Patients Completed NCT00763906 Phase 4
19 BaSES Trial: Basel Starch Evaluation in Sepsis Completed NCT00273728 Phase 4
20 Autonomic Nervous System Alteration Induce by Sepsis: Assessment and Prognosis Impact Completed NCT00835913 Phase 4
21 The Effects of Eicosapentaenoic Acid (EPA), Gamma-Linolenic Acid (GLA) and Antioxidants in the Treatment of Sepsis Completed NCT00329680 Phase 4
22 Pharmacokinetic/Pharmacodynamic Evaluation Amikacin in Critically Ill Patients Admitted at the Emergency Department Completed NCT02365272 Phase 4
23 Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
24 Influence of Age, Sepsis and SLCO1A2 Polymorphisms on Rocuronium Pharmacokinetics Completed NCT02399397 Phase 4
25 Early Use of Polymyxin B Hemoperfusion in Abdominal Sepsis Completed NCT00629382 Phase 4
26 Adrenal Cortical Function and Vitamin A Deficiency in Sepsis Completed NCT03152474 Phase 4
27 Low-dose Hydrocortisone in Acutely Burned Patients Completed NCT00149123 Phase 4
28 Intraoperative Protective Ventilation in Abdominal Surgery (IMPROVE Study) Completed NCT01282996 Phase 4
29 Evaluating the Influence of Ready-to-use (RTU) Parenteral Nutrition in the Clinical Outcome of Patients Study Completed NCT00798681 Phase 4
30 Effects of Vasopressors on Immune Response Completed NCT02675868 Phase 4
31 The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia Completed NCT01091571 Phase 4
32 The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation Completed NCT01099566 Phase 4
33 Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. Completed NCT00431691 Phase 4
34 Intravenous Clarithromycin in Septic Syndrome Completed NCT00297674 Phase 4
35 Ketamine Versus Etomidate for Rapid Sequence Intubation Completed NCT01823328 Phase 4
36 Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy Completed NCT00905853 Phase 4
37 Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock Recruiting NCT02716597 Phase 4
38 Early Goal Directed Sedation on Microcirculation in Septic Shock Recruiting NCT02612363 Phase 4
39 Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock Trial. VIPER-Sepsis (EudraCT no. 2016-000707-81) Recruiting NCT02875236 Phase 4
40 COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2 Recruiting NCT01639664 Phase 4
41 Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China Recruiting NCT02647554 Phase 4
42 Comparing Cytokines, Toxins Adsorbing oXiris Filter to ST150 Filter During CRRT in Patients With Septic Shock Recruiting NCT02600312 Phase 4
43 Hyperglycemia and Effects of Daily 100 mg Versus 200 mg of Hydrocortisone Therapy in Patients With Septic Shock Recruiting NCT02266264 Phase 4
44 Endotoxin Adsorber Hemoperfusion and Microcirculation Recruiting NCT01756755 Phase 4
45 Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue Recruiting NCT03120637 Phase 4
46 The Effect of Dexmedetomidine on Microcirculation in Severe Sepsis Recruiting NCT02109965 Phase 4
47 Effects of Levosimendan and Milrinone on Left and Right Ventricular Function in Septic Cardiomyopathy Recruiting NCT02640846 Phase 4
48 Fluid Responsiveness Evaluation in Sepsis-associated Hypotension Recruiting NCT02837731 Phase 4
49 Gelatin in ICU and Sepsis Recruiting NCT02715466 Phase 4
50 Importance of the Infusion Rate for the Plasma Expanding Effect of 5% Albumin in the Septic Patient Recruiting NCT03153306 Phase 4

Search NIH Clinical Center for Toxic Shock Syndrome

Cochrane evidence based reviews: shock, septic

Genetic Tests for Toxic Shock Syndrome

Anatomical Context for Toxic Shock Syndrome

MalaCards organs/tissues related to Toxic Shock Syndrome:

39
T Cells, Breast, Monocytes, Skin, B Cells, Neutrophil, Bone

Publications for Toxic Shock Syndrome

Articles related to Toxic Shock Syndrome:

(show top 50) (show all 675)
id Title Authors Year
1
Group B Streptococcal Toxic Shock Syndrome and covR/S Mutations Revisited. ( 27983484 )
2017
2
HLA-DR polymorphisms influence in vivo responses to staphylococcal toxic shock syndrome toxin-1 in a transgenic mouse model. ( 27863161 )
2017
3
Vaccine against toxic shock syndrome in a first-in-man clinical trial. ( 27918218 )
2017
4
Streptococcal Toxic Shock Syndrome Caused by Group G Streptococcus, United Kingdom. ( 27983491 )
2017
5
Intrauterine device infection causing concomitant streptococcal toxic shock syndrome and pelvic abscess with Actinomyces odontolyticus bacteraemia. ( 26965406 )
2016
6
Toxic Shock Syndrome Caused by Methicillin-Resistant Staphylococcus aureus (MRSA) After Expander-Based Breast Reconstruction. ( 26813150 )
2016
7
Profuse watery diarrhoea: An unusual presenting feature of streptococcal toxic shock syndrome. ( 27124845 )
2016
8
Local Epidermal Growth Factor Receptor Signaling Mediates the Systemic Pathogenic Effects of Staphylococcus aureus Toxic Shock Syndrome. ( 27414801 )
2016
9
Lipopolysaccharide-Induced Toxic Shock Syndrome in Rabbits. ( 26676037 )
2016
10
Streptococcal Toxic Shock Syndrome: Life Saving Role of Peritoneal Lavage and Drainage. ( 27579001 )
2016
11
A fatal case of streptococcal toxic shock syndrome caused by Streptococcus suis carrying tet (40) and tet (O/W/32/O), Italy. ( 27553071 )
2016
12
Polymyxin-B immobilized column-direct hemoperfusion for adolescent toxic shock syndrome. ( 27804246 )
2016
13
Toxic Shock Syndrome: An Unusual Organism. ( 27432040 )
2016
14
Toxic shock syndrome in Australian children. ( 27117838 )
2016
15
Recurrent SDSE bacteraemia resulting in streptococcal toxic shock syndrome in a patient with Noonan syndrome. ( 27485878 )
2016
16
Acute encephalopathy with biphasic seizures and late reduced diffusion associated with staphylococcal toxic shock syndrome caused by burns. ( 27117386 )
2016
17
Clostridium Sordellii as an Uncommon Cause of Fatal Toxic Shock Syndrome in a Postpartum 33-Year-Old Asian Woman, and the Need for Antepartum Screening for This Clostridia Species in the General Female Population. ( 27371657 )
2016
18
A long road to a preventative for toxic shock syndrome. ( 27296692 )
2016
19
Invariant NKT cells are pathogenic in the HLA-DR4-transgenic humanized mouse model of toxic shock syndrome and can be targeted to reduce morbidity. ( 28035011 )
2016
20
Mild forms of toxic shock syndrome toxin-1-mediated exanthematous disease related to Staphylococcus aureus infection. ( 26923257 )
2016
21
Swift Intrahepatic Accumulation of Granulocytic Myeloid-Derived Suppressor Cells in a Humanized Mouse Model of Toxic Shock Syndrome. ( 26908735 )
2016
22
Preliminary investigation of human serum albumin-VI^ inhibition on toxic shock syndrome induced by staphylococcus enterotoxin B inA vitro and inA vivo. ( 26792715 )
2016
23
Cytokine profile and T cell receptor analysis in a case of postpartum toxic shock syndrome. ( 27154311 )
2016
24
Recurrent Streptococcus agalactiae Toxic Shock Syndrome Triggered by a Tumor Necrosis Factor-I+ Inhibitor. ( 27803422 )
2016
25
Group A streptococcal toxic shock syndrome secondary to necrotizing pelvic inflammatory disease in a postmenopausal woman. ( 27419069 )
2016
26
Right in Front of Our Eyes: Evolution of Streptococcal Toxic Shock Syndrome with Ischemic Optic Neuropathy. ( 27903001 )
2016
27
High prevalence of toxic shock syndrome toxin-producing epidemic methicillin-resistant Staphylococcus aureus 15 (EMRSA-15) strains in Kuwait hospitals. ( 27222714 )
2016
28
Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial. ( 27296693 )
2016
29
Clinically mild encephalitis/encephalopathy with a reversible splenial lesion caused by methicillin-sensitive Staphylococcus aureus bacteremia with toxic shock syndrome: a case report. ( 27091490 )
2016
30
The SaeRS Two-Component System Is a Direct and Dominant Transcriptional Activator of Toxic Shock Syndrome Toxin 1 in Staphylococcus aureus. ( 27457715 )
2016
31
Veno-arterial extracorporeal membrane oxygenation for Streptococcus pyogenes toxic shock syndrome in pregnancy. ( 26758056 )
2016
32
A Term Infant of Neonatal Toxic Shock Syndrome-Like Exanthematous Disease Complicated with Hemophagocytic Syndrome. ( 27760897 )
2016
33
Relevance of spontaneous fabT mutations to a streptococcal toxic shock syndrome to non-streptococcal toxic shock syndrome transition in the novel-type Streptococcus pyogenes isolates that lost a salRK. ( 26861052 )
2016
34
Spontaneous mutations in Streptococcus pyogenes isolates from streptococcal toxic shock syndrome patients play roles in virulence. ( 27349341 )
2016
35
Poster 80 Bilateral Lower Extremity Amputation after Toxic Shock Syndrome Presents with Locked Knee: AA Case Report. ( 27672849 )
2016
36
Unusual staphylococcal toxic shock syndrome presenting as a scarlet-like fever. ( 26543563 )
2015
37
Vaccination with non-toxic mutant toxic shock syndrome toxin-1 induces IL-17-dependent protection against Staphylococcus aureus infection. ( 25857736 )
2015
38
Staphylococcal toxic shock syndrome caused by tampon use. ( 25692047 )
2015
39
Toxic Shock Syndrome detected at 21 weeks' gestation complicating acute chorioamnionitis with intact sac. ( 25910989 )
2015
40
PHENOTYPIC AND GENOTYPIC DETECTION OF ENTEROTOXINS, TOXIC SHOCK SYNDROME TOXIN-1 AND OF METHICILLIN RESISTANCE IN STAPHYLOCOCCUS AUREUS ISOLATED FROM RETAIL READY-TO-EAT FOODS IN NORTHEASTERN THAILAND. ( 26513910 )
2015
41
Molecular typing of toxic shock syndrome toxin-1- and Enterotoxin A-producing methicillin-sensitive Staphylococcus aureus isolates from an outbreak in a neonatal intensive care unit. ( 26321006 )
2015
42
Streptococcal Necrotizing Fasciitis with Toxic Shock Syndrome and Rapid Fatal Outcome. ( 26506762 )
2015
43
Toxic shock syndrome. ( 25878235 )
2015
44
Early Differentiation of Kawasaki Disease Shock Syndrome and Toxic Shock Syndrome in a Pediatric Intensive Care Unit. ( 26222065 )
2015
45
A confirmed case of toxic shock syndrome associated with the use of a menstrual cup. ( 26361491 )
2015
46
Prevalence of antibody to toxic shock syndrome toxin-1 in burn patients. ( 25553286 )
2015
47
Management of primary iliopsoas abscess in an immunocompetent patient followed by streptococcal toxic shock syndrome: A case report. ( 27489682 )
2015
48
MRSA Clonal Complex 22 Strains Harboring Toxic Shock Syndrome Toxin (TSST-1) Are Endemic in the Primary Hospital in Gaza, Palestine. ( 25781188 )
2015
49
Increased prevalence of group A streptococcus isolates in streptococcal toxic shock syndrome cases in Japan from 2010 to 2012. ( 25703404 )
2015
50
Toxic shock syndrome due to methicillin-resistant Staphylococcus aureus infection after a pediatric scald burn. ( 26803714 )
2015

Variations for Toxic Shock Syndrome

Expression for Toxic Shock Syndrome

Search GEO for disease gene expression data for Toxic Shock Syndrome.

Pathways for Toxic Shock Syndrome

Pathways related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 82)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 C1S CD40 CIITA CXCL8 HMGB1 IFNG
2
Show member pathways
13.88 CD40 CXCL8 IL10 IL1B IL2 IL4
3
Show member pathways
13.75 CD40 CXCL8 EDNRA IFNG IL10 IL1B
4
Show member pathways
13.62 CXCL8 IFNG IL10 IL1B IL2 IL4
5
Show member pathways
13.5 CD40 CXCL8 IL10 IL1B IL2 IL4
6
Show member pathways
13.44 CD40 CIITA CXCL8 IFNG IL10 IL1B
7
Show member pathways
13.4 CD40 CXCL8 IL10 IL1B IL2 IL4
8
Show member pathways
13.27 CD40 HMGB1 IFNG IL1B IL2 IL4
9
Show member pathways
13.03 CD40 CXCL8 IFNG IL10 IL1B IL2
10
Show member pathways
12.87 CIITA CXCL8 IFNG IL1B IL2 IL4
11
Show member pathways
12.84 IL2 IL4 IL6 LTA TNF
12
Show member pathways
12.84 CXCL8 HMGB1 IFNG IL1B IL6 TNF
13
Show member pathways
12.81 CD40 IL1B IL2 IL6 LTA TNF
14
Show member pathways
12.75 CD40 IFNG IL10 IL2 IL4 TNF
15
Show member pathways
12.74 CD40 IFNG IL1B LTA TNF
16
Show member pathways
12.74 CD40 CIITA CXCL8 IFNG IL10 IL1B
17
Show member pathways
12.72 IFNG IL10 IL1B IL2 IL4 IL6
18
Show member pathways
12.71 IFNG IL10 IL1B IL2 IL6 TNF
19 12.66 CIITA IFNG IL10 IL1B IL2 IL4
20
Show member pathways
12.57 IFNG IL10 IL1B IL2 IL4 IL6
21
Show member pathways
12.54 IFNG IL2 IL4 TNF
22 12.54 CD40 IL2 IL6 LTA TNF
23
Show member pathways
12.47 IFNG IL1B IL2 IL4 IL6 TNF
24
Show member pathways
12.47 CXCL8 IFNG IL1B IL4 IL6 TNF
25
Show member pathways
12.4 CXCL8 IFNG IL1B IL6 TNF
26
Show member pathways
12.38 CD40 CIITA IFNG IL10 IL1B IL4
27 12.36 CIITA IFNG IL10 IL1B IL6 TNF
28
Show member pathways
12.35 IFNG IL10 IL2 IL4 IL6
29
Show member pathways
12.32 CXCL8 IFNG IL1B IL4 IL6 TNF
30 12.31 CXCL8 IL10 IL1B IL6 TNF
31 12.15 IFNG IL10 IL2 IL4 IL6 TNF
32 12.13 CXCL8 IL10 IL1B IL4 IL6 TNF
33
Show member pathways
12.09 IFNG IL1B IL2 IL4
34 12.08 CXCL8 IFNG IL1B IL2 IL4 IL6
35 12.07 IL1B IL6 LTA TNF
36 12.06 CXCL8 IFNG IL1B IL6
37
Show member pathways
12.04 IFNG IL1B IL4 IL6
38 12.04 CD40 CXCL8 IL1B LTA TNF
39 12.04 CXCL8 IFNG IL10 IL1B IL6 TNF
40 12.02 CXCL8 IL1B IL6 TNF
41 12.01 IL1B IL4 IL6 TNF
42 12.01 CXCL8 IFNG IL1B IL6 TNF
43
Show member pathways
11.98 IFNG IL10 IL1B IL2 IL6 LTA
44 11.96 CXCL8 IFNG IL1B IL6
45 11.96 CXCL8 IFNG IL2 IL4 IL6
46
Show member pathways
11.92 CXCL8 IFNG IL2 IL4 TNF
47 11.91 IFNG IL10 IL1B IL2 IL6 TNF
48 11.89 C1S CXCL8 IL10 IL1B IL6 TNF
49